Research & Treatment Updates
Researchers at the Celiac Disease Genomic, Microbiome, and Metabolomic (CDGEMM) study based at the MassGeneral Hospital for Children compared the gut microbiomes of infants who went on to develop celiac disease (CD) to those who did not develop it. Changes were noted 18 months prior to the onset of CD, leading researchers to believe that they will be able to predict who will develop CD. Read more here.
Here are updates on some potential treatments for CD:
In a proof of concept trial published in the New England Journal of Medicine, ZED1227 was found to attenuate gluten-induced damage to villi. Click here to read about this.
A small study published in Gastroenterology found that TAK-101 may prevent gluten-induced immune activation in people with celiac disease. Click here to read about this.
News About CD-Related Studies
Researchers from the Division of Gastroenterology and Hepatology at the Mayo Clinic, in conjunction with others, conducted a study to investigate the accuracy of the immunoglobulin A tissue transglutaminase, or tTG-IgA, blood screen for CD. The researchers found verification bias due to people with positive tTG-IgA result being more likely to have an endoscopy and biopsy of the small intestine than people with a negative tTG-IgA result. Researchers concluded that there is no concern about positive tTG-IgA results, but that caution should be exercised when interpreting a negative tTG-IgA result when screening for CD. Click here to read about this.
This article warns that prices may be increasing for GF foods.
Here are some tips on how to save money when shopping for GF foods.
Researchers looking into improving the nutritional value of GF bread products while making them more palatable wonder if psyllium may be the answer. Click here to read about this.